Tapping the potential of GLP-1 drugs requires integrated care and overcoming inequities, executives say

Taking stock of the drug industry, from the lab to the medicine chest

March 20, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Brooke Alexander for STAT STAT+ | Tapping the potential of GLP-1 drugs requires integrated care and overcoming inequities, executives say At STAT's Breakthrough Summit East, the CEOs of Ro and Included Health said the the U.S. health care system poses obstacles to maximizing that potential. By Ed Silverman STAT+ | HHS agency responsible for health care quality research threatened with mass layoffs Insiders say the HHS agency, which focuses on the safety and practical use of health care, could experience staff cuts of 80% to 90%. By John Wilkerson STAT+ | Sutro Bio joins biotech's zombie army. When will this insanity end? In this edition of "Adam's Biotech Scorecard," a closer look at a company that appears determined to persist in its plans in the face of signs it shouldn't. By Adam Feuerstein Adobe STAT+ | Why we don't need AI to be board-certified In this edition of STAT's AI Prognosis newsletter: The trouble with using medical exams as benchmarks for evaluating health AI models, and more. By Brittany Trang

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser